Европейская академия естественных наук Hannover E.V.

Jian-Jun Li

Dr. Li developed a novel needle-catheter technique, which can directly inject plasmid or other drugs into the myocardium. This technique has been modified as a new device by JNJ company for mapping the focus of arrhythmias and treating patients with tachycardia. He raised the important hypothesis (Should atherosclerosis be considered a cancer of the vascular wall? and Atheroscleritis is a more rational term for the pathological entity currently known as atherosclerosis). These hypothesis promoted the future studies on the association of inflammation, cancer and atherosclerosis. More importantly, He is a pioneer in clinical scientist and performed a series of studied on the relation of inflammation to coronary artery disease (CAD) including different clinical entities of CAD covering acute coronary syndrome, stable CAD, cardiac syndrome X, slow coronary flow, variant angina, coronary artery ectasia, rebound phenomenon of inflammation after abrupt cessation of statin therapy, and in-stent restenosis. He won a prize of Chinese Medical Association due to those works.

He has also created the first clinical platform for prevention and treatment of lipid disorders in Chinese population, and made pioneering contributions to the development this relatively hysteretic discipline of cardiovascular medicine in China. Among more than ten years (2010-2013), Professor Li moved his major research interests from interventional cardiology into the dyslipidemia. He established a first clinic lipid Center in China and firstly used lipoprotein apheresis technique to treat patients with refractory dyslipidemia such as familial hypercholesterolemia (FH). He became a first man who intensively investigate the characteristics of Chinese patients with FH, which the area including the prevalence of FH, genetic analysis, the role of lipoprotein (a) [Lp(a)] and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in FH, and clinical diagnosis/treatment in Chinese FH patients. He developed the simplified Chinese Criteria FH (SCCFH), which was widely applied by Chinese doctors. He published more than fifty FH-related, high-quality SCI-indexed articles in international peer-review cardiovascular journals. At same time, Professor Li keenly grasped the research hotspot concerning lipid filed. At the beginning of Lipid Center establishment, he started the several research projects about the regulation of PCSK9 expression, and the role of cardiometabolic factors in predicting the prognosis of patients with CAD. More than 200 articles were derived from those projects, and the results were cited by more than 5000 times by scientists around the world. Hence, professor Li has been accredited to be a pioneer regarding lipid filed in China.

During past two years, Professor Li take the lead to write and publish three important documents regarding lipid controlling in Chinese people: two consensus statement articles [Li J-J, et al. Role of omega-3 fatty acids in the prevention and treatment of cardiovascular Diseases: A consensus statement from the Experts’ Committee Of National Society Of Cardiometabolic Medicine, Front Pharmacol 2022;1069992; Li J-J, et al. Lipoprotein(a) and Cardiovascular Disease in Chinese Population: A Beijing Heart Society Expert Scientific Statement. JACC: Asia 2022;2(8):653-665.] and one lipid guideline in cardiovascular filed (Li J-J, et al. 2023 Chinese guideline for lipid Management. Front Pharmacol 2023;1190934.).

 

вверх

Энциклопедия ЕАЕН

 ¦  Impressum  ¦  Контакт